# Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

> **NCT07648069** · PHASE1 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 16 (estimated)

## Conditions studied

- Soft Tissue Sarcoma (STS)
- Osteosarcoma

## Interventions

- **BIOLOGICAL:** Neoantigen vaccine + specific lymphocytes + anti-PD1 antibody
- **BIOLOGICAL:** Neoantigen vaccine + anti-PD1 antibody

## Key facts

- **NCT ID:** NCT07648069
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-03
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07648069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07648069, "Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07648069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*